
Real-world evidence (RWE) is key to accelerating oncology approvals
23 June 2021
- RWE has emerged as a valuable complementary resource to provide information beyond what is learned from randomized clinical trials
- Advances in technology and analytics are enabling real-world data to be gathered in real time and analyzed to help make clinical, payer, policy, and regulatory decisions
- The capability of RWE to create a more robust view of the benefits and risks of oncology treatments among all patients eligible for therapy is critically important
Click here to learn more.
About SVMPharma
SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.
For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com
ref: JUN2021CW002